0
0
NEW DELHI – In a significant breakthrough for ophthalmology, a recent study has provided compelling evidence that a surgically implanted device may help to slow the progression of vision loss in individuals with macular telangiectasia type 2 (MacTel), a rare and debilitating retinal disorder. The findings, published in the journal NEJM Evidence, highlight a new therapeutic approach for a disease that has historically lacked approved treatment options.
The study, a culmination of two Phase III clinical trials, evaluated a device known as ENCELTO, a tiny implant that continuously releases ciliary neurotrophic factor (CNTF)—a protein known to protect retinal nerve cells. The implant, which houses genetically modified retinal pigment epithelial cells within a collagen-based capsule, is designed to deliver this therapeutic protein directly to the affected area, shielding the cells from immune rejection and ensuring a long-term, localized delivery.
MacTel is a slow-progressing condition that gradually destroys the central vision essential for tasks like reading and recognizing faces. The new findings show that the ENCELTO implant significantly slowed the loss of photoreceptors—the light-sensing nerve cells critical for vision—compared to control groups. In one trial, the implant resulted in a 54.8% reduction in the rate of ellipsoid zone loss, a key marker of cell degeneration. A second trial showed a 30.6% reduction, a result that was still statistically significant.
Professor Martin Friedlander, a key contributor to the research, commented on the significance of the findings, stating, “This is a step toward redefining how we think about vision loss. Instead of waiting for cells to die, we’re learning how to protect and preserve them.” The success of ENCELTO, which has received U.S. FDA approval, is being hailed as the first authorized treatment for MacTel and the first cell-based neuroprotective treatment for any neurodegenerative retinal disease.
Disclaimer
The information in this article is for general informational purposes only and does not constitute medical advice. It is not a substitute for professional diagnosis or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.
Reference
- Mathrubhumi English. “Surgical implant may help slow vision loss from rare eye disease: study.” Mathrubhumi.com, https://english.mathrubhumi.com/lifestyle/health/surgical-implant-may-help-slow-vision-loss-from-rare-eye-disease-study-pspm6gmt.
